Innate Pharma SA
IPHA2.110USD
-0.040-1.86%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
176.84MMarktkapitalisierung
--KGV TTM
mehr Informationen über Innate Pharma SA Unternehmen
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Unternehmensinformationen
BörsenkürzelIPHA
Name des UnternehmensInnate Pharma SA
IPO-datumOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeOct 31
Addresse117 avenue de Luminy
StadtMARSEILLE
BörseNASDAQ Global Select Consolidated
LandFrance
Postleitzahl13009
Telefon33430303030
Websitehttps://www.innate-pharma.com/
BörsenkürzelIPHA
IPO-datumOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ms. Claire De Saint-blanquat
Ms. Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
--
--
Dr. Sally Bennett
Dr. Sally Bennett
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.02%
Other
99.84%
Aktionäre
Aktionäre
Anteil
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.02%
Other
99.84%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.05%
Hedge Fund
0.04%
Investment Advisor
0.01%
Other
99.83%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
17
157.41K
0.17%
-54.22K
2025Q1
22
261.37K
0.29%
-22.81K
2024Q4
23
278.64K
0.34%
-188.16K
2024Q3
25
406.53K
0.50%
-579.77K
2024Q2
27
405.72K
0.50%
-529.94K
2024Q1
29
344.92K
0.22%
-517.69K
2023Q4
32
202.70K
0.25%
-1.13M
2023Q3
36
377.53K
0.47%
-1.02M
2023Q2
36
293.58K
0.36%
-1.21M
2023Q1
33
404.31K
0.50%
-1.20M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AllianceBernstein L.P.
60.75K
0.07%
+36.48K
+150.33%
Jun 30, 2024
Morgan Stanley & Co. International Plc
43.52K
0.05%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.27K
0.03%
+12.41K
+104.73%
Mar 31, 2025
Millennium Management LLC
15.33K
0.02%
+15.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
9.00K
0.01%
+5.49K
+156.44%
Mar 31, 2025
GAMMA Investing LLC
2.23K
0%
+2.23K
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
675.00
0%
--
--
Mar 31, 2025
Barclays Bank PLC
307.00
0%
--
--
Mar 31, 2025
Optiver Holding B.V.
101.00
0%
--
--
Mar 31, 2025
Tower Research Capital LLC
3.00
0%
+3.00
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
ActivePassive International Equity ETF
Anteil0%
DFA Dimensional Intl Sustainability Core 1 ETF
Anteil0%
DFA Dimensional International Core Equity 2 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
